Close Menu

NEW YORK (360Dx) – Sight Diagnostics said on Thursday that it has raised $27.8 million in Series C funding that it will use to continue the global expansion of its artificial intelligence-based point-of-care blood diagnostics system, called OLO.

Sight Diagnostics said it will also use the funding to support its regulatory efforts in the US and to expand its menu of diagnostic tests. Company CTO Sarah Levy said in a statement that the new financing will allow it to expand R&D activities to develop applications beyond complete blood counts, currently the main use for OLO.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.